Overzicht belangen werkgroepleden
Uit Richtlijnen HIV
(Verschil tussen bewerkingen)
| Regel 147: | Regel 147: | ||
|- | |- | ||
| Jet Gisolf | | Jet Gisolf | ||
| - | | Roche | + | | Roche |
| | | | ||
| | | | ||
| - | | align="center" | x | + | | align="center" | x |
| | | | ||
|- | |- | ||
| | | | ||
| - | | Merck | + | | Merck |
| | | | ||
| | | | ||
| - | | align="center" | x | + | | align="center" | x |
| | | | ||
|- | |- | ||
| | | | ||
| - | | Gilead | + | | Gilead |
| | | | ||
| | | | ||
| - | | align="center" | x | + | | align="center" | x |
| | | | ||
|- | |- | ||
| | | | ||
| - | | Shering Plough | + | | Shering Plough |
| | | | ||
| | | | ||
| - | | align="center" | x | + | | align="center" | x |
| | | | ||
|- | |- | ||
| | | | ||
| - | | Abbott | + | | Abbott |
| | | | ||
| | | | ||
| - | | align="center" | x | + | | align="center" | x |
| | | | ||
|- | |- | ||
| Regel 251: | Regel 251: | ||
| | | | ||
|} | |} | ||
| + | |||
| + | Door de werkgroepleden opgegeven relaties in de periode 2005-2010 | ||
Versie op 3 jun 2010 18:16
| Naam | Firma |
Consultatie/ advisering |
Wetenschappelijk onderzoek |
Congres/ andere reis | Cursus |
| Kees Brinkman | Viiv | x | x | x | |
| BMS | x | ||||
| MSD | x | x | |||
| Gilead | x | x | x | ||
| Roche | x | ||||
| Abbott | x | x | |||
| Jansen-Tibotec | x | x | x | ||
| Mariska Tuut | Geen | ||||
| Suzanne Geerlings | MSD | x | x | ||
| GSK | x | ||||
| BMS | x | x | |||
| Gilead | x | x | |||
| Abbott | x | x | |||
| Jansen Cilag (Tibotec) | x | ||||
| Pfizer | x | ||||
| Jet Gisolf | Roche | x | |||
| Merck | x | ||||
| Gilead | x | ||||
| Shering Plough | x | ||||
| Abbott | x | ||||
| Gerrit Schreij | Viiv Healthcare | x | x | ||
| Gilead | x | ||||
| Tibotec | x | ||||
| Roche | x | ||||
| MSD | x | ||||
Door de werkgroepleden opgegeven relaties in de periode 2005-2010